Supreme Court grants three-day extension on ruling over abortion drug mifepristone

The U.S. Supreme Court announced it will take an additional three days before issuing a decision in the case concerning the abortion medication mifepristone.

The case, Louisiana v. FDA, reached the high court after a federal appeals panel reinstated a rule that would require providers to dispense mifepristone in person, overturning a prior allowance for mail distribution.

The brief delay means the Court will review arguments about the FDA’s regulatory authority and the impact on access to the drug, keeping the issue pending for patients and manufacturers.